estratto:
There may still be further to go. Investment bank Morgan Stanley yesterday cut its target price for Teva from $36 to $16. The new price target implies a 14% further drop in Teva's share price. Two international rating agencies have downgraded their rating for Teva's debt. Moody's lowered its rating from Baa2 to Baa3, and Fitch lowered its rating from BBB to BBB minus, one level higher than junk bonds.